InnoCare Receives Approval to Initiate Clinical Evaluation of ICP-248 in Combination with Orelabrutinib for Treating Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China
Shots:
- InnoCare Pharma has received IND approval to initiate the clinical evaluation of ICP-248 combined with orelabrutinib as a 1L treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in China
- The multicenter, randomized-controlled, open-label clinical trial will investigate the safety and efficacy ICP-248 + orelabrutinib vs immunochemotherapy for treating CLL/SLL patients who are treatment-naïve
- ICP-248 (oral) is a novel, bioavailable BCL2-selective inhibitor that exhibits anti-tumor activity by selectively inhibiting BCL2 and restoring the programmed cell death mechanism
Ref: Businesswire | Image: Innocare
Related News:- InnoCare Pharma Reports the IND Clearance of ICP-248 from the US FDA for Hematologic Malignancies
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
